The Bottom Line GLP-1 drugs can benefit older adults with obesity, type 2 diabetes, or elevated cardiovascular risk
Track stool number, appearance, and timing versus doses
Plus, the company offers a dividend with an attractive payout of $6 per share annually
Food and Drug Administration (FDA) and World Health Organization (WHO) have warned about unapproved injectable products
9 This paper presents a detailed overview of the biomarker function of TMAO in the gut-organ axis, as well as the regulation mechanism of TMAO on the gut-organ axis, particularly in relation to the crosstalk mechanisms involved in cell death
GDMT for HFrEF typically includes evidence-based beta-blockers, angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2is), particularly in patients with obesity or T2DM [53]